D-amino acid retro-inverso FOXO4 peptide. Investigated as a senolytic agent in aging biology research, with preclinical studies examining its effects on p53-mediated apoptosis in senescent cells.
FOXO4-DRI is a research compound available through our china peptide catalog as a finished, lyophilized vial from an established Chinese manufacturer. It belongs to the D-retro-inverso peptidomimetic (DRI peptide)
Research Areas
Senolytic biology, senescent cell elimination, p53 signaling, FOXO4-p53 interaction, aging models
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| FOXO4-DRI | 10 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS ([“HPLC”,“LC-MS”,“Assay”]) . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .
**Where provided, these documents reflect the manufacturer’s batch testing for this compound.
Research Areas
Senolytic Mechanism Research FOXO4-DRI is a primary research tool for studying FOXO4-p53-mediated senescent cell survival. Research has examined whether disrupting this interaction is sufficient to induce apoptosis selectively in senescent versus non-senescent cell populations. In vitro studies using senescent fibroblast and epithelial cell models have assessed apoptotic induction markers (cleaved caspase-3, PARP cleavage, Annexin V) following FOXO4-DRI treatment, with selectivity comparisons to normal cycling cells. Senescent Cell Biology in Aging Models Preclinical studies in naturally aged and accelerated aging (e.g., doxorubicin-treated) rodent models have examined FOXO4-DRI administration in the context of senescent cell clearance. Research outcomes have included histological assessments of p16-positive and p21-positive senescent cell burden in tissues, along with functional endpoints such as tissue inflammation markers, fur density and appearance, and renal function — as used in the original Nature paper characterizing the compound. DRI Peptidomimetic Technology The D-retro-inverso modification is a tool for generating metabolically stable peptidomimetics that preserve protein-binding geometry while resisting proteolytic degradation. FOXO4-DRI is a well-characterized example of this approach and is used in structural biology and pharmacology research to study how DRI modifications affect target affinity, cell penetration, and selectivity compared to the native L-amino acid peptide sequence. ## Sourcing FOXO4-DRI From China
FOXO4-DRI is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:
- Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
- Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
- Research-use discipline. Like every listing in our catalog, FOXO4-DRI is supplied for laboratory research use only, under strict research-use terms.
For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| FOXO4-DRI | 10 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS ([“HPLC”,“LC-MS”,“Assay”]) . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .
**Where provided, these documents reflect the manufacturer’s batch testing for this compound.
Research Areas
Senolytic Mechanism Research FOXO4-DRI is a primary research tool for studying FOXO4-p53-mediated senescent cell survival. Research has examined whether disrupting this interaction is sufficient to induce apoptosis selectively in senescent versus non-senescent cell populations. In vitro studies using senescent fibroblast and epithelial cell models have assessed apoptotic induction markers (cleaved caspase-3, PARP cleavage, Annexin V) following FOXO4-DRI treatment, with selectivity comparisons to normal cycling cells. Senescent Cell Biology in Aging Models Preclinical studies in naturally aged and accelerated aging (e.g., doxorubicin-treated) rodent models have examined FOXO4-DRI administration in the context of senescent cell clearance. Research outcomes have included histological assessments of p16-positive and p21-positive senescent cell burden in tissues, along with functional endpoints such as tissue inflammation markers, fur density and appearance, and renal function — as used in the original Nature paper characterizing the compound. DRI Peptidomimetic Technology The D-retro-inverso modification is a tool for generating metabolically stable peptidomimetics that preserve protein-binding geometry while resisting proteolytic degradation. FOXO4-DRI is a well-characterized example of this approach and is used in structural biology and pharmacology research to study how DRI modifications affect target affinity, cell penetration, and selectivity compared to the native L-amino acid peptide sequence.
Compound Profile
FOXO4-DRI is a D-retro-inverso (DRI) peptidomimetic based on a domain of the FOXO4 transcription factor — specifically the region that interacts with p53 in senescent cells. The DRI modification inverts the amino acid sequence and substitutes D-amino acids for L-amino acids throughout, producing a peptide that is highly resistant to proteolytic degradation in biological media while retaining the ability to penetrate cells and interact with its protein target. The compound was identified in the context of senescent cell biology and has become a research tool for studying targeted elimination of senescent cells — a cellular phenotype associated with aging and age-related tissue dysfunction. The biological mechanism proposed for FOXO4-DRI centers on disrupting the FOXO4-p53 interaction in senescent cells. In senescent cells — unlike normal proliferating or quiescent cells — FOXO4 is reported to bind p53 and retain it in the nucleus, suppressing the p53-dependent apoptotic pathway that would otherwise eliminate the cell. FOXO4-DRI is hypothesized to competitively disrupt this interaction, releasing p53 from FOXO4 retention and restoring apoptotic signaling specifically in senescent cells. This selective mechanism — exploiting a senescence-specific FOXO4 activity — is the key feature distinguishing it from broadly cytotoxic approaches in senolytic research. Peptides of China supplies FOXO4-DRI as a lyophilized powder at 99%+ purity, verified by HPLC and Mass Spectrometry. Every batch is tested by the manufacturer for purity and concentration as part of routine quality control. All products are for laboratory research use only and are not for human consumption.
Profile
Research Areas
Senolytic biology, senescent cell elimination, p53 signaling, FOXO4-p53 interaction, aging models
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| FOXO4-DRI | 10 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS ([“HPLC”,“LC-MS”,“Assay”]) . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .
**Where provided, these documents reflect the manufacturer’s batch testing for this compound.
Research Areas
Senolytic Mechanism Research FOXO4-DRI is a primary research tool for studying FOXO4-p53-mediated senescent cell survival. Research has examined whether disrupting this interaction is sufficient to induce apoptosis selectively in senescent versus non-senescent cell populations. In vitro studies using senescent fibroblast and epithelial cell models have assessed apoptotic induction markers (cleaved caspase-3, PARP cleavage, Annexin V) following FOXO4-DRI treatment, with selectivity comparisons to normal cycling cells. Senescent Cell Biology in Aging Models Preclinical studies in naturally aged and accelerated aging (e.g., doxorubicin-treated) rodent models have examined FOXO4-DRI administration in the context of senescent cell clearance. Research outcomes have included histological assessments of p16-positive and p21-positive senescent cell burden in tissues, along with functional endpoints such as tissue inflammation markers, fur density and appearance, and renal function — as used in the original Nature paper characterizing the compound. DRI Peptidomimetic Technology The D-retro-inverso modification is a tool for generating metabolically stable peptidomimetics that preserve protein-binding geometry while resisting proteolytic degradation. FOXO4-DRI is a well-characterized example of this approach and is used in structural biology and pharmacology research to study how DRI modifications affect target affinity, cell penetration, and selectivity compared to the native L-amino acid peptide sequence.